ProcartaPlex™ Mouse Cytokine & Chemokine Panel 1A, 36plex
ProcartaPlex™ Mouse Cytokine & Chemokine Panel 1A, 36plex
Invitrogen™

ProcartaPlex™ Mouse Cytokine & Chemokine Panel 1A, 36plex

El panel 1A ProcartaPlex 36-Plex de citocina y quimiocina de ratón permite el estudio de la función inmunitaria mediante elMás información
Have Questions?
Número de catálogoCantidad
EPX360-26092-90196 pruebas
Número de catálogo EPX360-26092-901
Precio (CLP)
7.918.883
Each
Añadir al carro de la compra
Cantidad:
96 pruebas
Precio (CLP)
7.918.883
Each
Añadir al carro de la compra
El panel 1A ProcartaPlex 36-Plex de citocina y quimiocina de ratón permite el estudio de la función inmunitaria mediante el análisis de 36 proteínas diana en un solo pocillo a través de la tecnología Luminex xMAP. El panel se compone de cuatro subpaneles modulares que disponen de una amplia pantalla inicial para determinar los elementos diana de interés, así como estudios posteriores que analizan los subconjuntos funcionales específicos de citocinas y que pueden adquirirse por separado. Los subpaneles son totalmente combinables entre ellos o con los ensayos individuales simples correspondientes a los objetivos del panel. Los mismos elementos diana se pueden encontrar en el panel práctico 1A ProcartaPlex 36-Plex de citocina y quimiocina de ratón (n.º de ref. EPXR360-26092-901) que está en un formato listo para su uso que requiere menos pipeteo.

Los paneles preconfigurados ProcartaPlex se han probado exhaustivamente para determinar la capacidad combinatoria, la interferencia y la reactividad cruzada de los analitos con el fin de proporcionar el mayor nivel de validación y precisión. Todos los paneles ProcartaPlex se suministran con los reactivos necesarios para realizar el ensayo.

Los paneles multiplex ProcartaPlex están disponibles en múltiples formatos en seis especies (humano, ratón, rata, primate no humano, porcino y canino). Visite nuestra página de inmunoensayos ProcartaPlex para obtener más información y consultar los productos disponibles.

Lista de objetivos [región de gránulos]:
Th1/Th2: GM-CSF [42], IFN gamma [38], IL-1 beta [19], IL-2 [20], IL-4 [26], IL-5 [27], IL-6 [28], IL-12p70 [39], IL-13 [35], IL-18 [66], TNF alpha [45]
Th9/Th17/Th22/Treg: IL-9 [34], IL-10 [13], IL-17A (CTLA-8) [52], IL-22 [33], IL-23 [37], IL-27 [36]
Citocinas inflamatorias: G-CSF (CSF-3) [12], IFN alfa [30], IL-3 [14], IL-15/IL-15R [54], IL-28 [64], IL-31 [76], IL-1 alfa [56], LIF [18], ENA-78 (CXCL5) [57], M-CSF [21]
Quimiocinas: Eotaxin (CCL11) [62], GRO alfa (CXCL1) [43], IP-10 (CXCL10) [22], MCP-1 (CCL2) [51], MCP-3 (CCL7) [48], MIP-1 alfa (CCL3) [47], MIP-1 beta (CCL4) [72], MIP-2 [55], RANTES (CCL5) [44]

Acerca de los ensayos ProcartaPlex para la plataforma Luminex
Los inmunoensayos ProcartaPlex están basados en los principios de un ELISA de tipo sándwich, que usa dos anticuerpos específicos unidos a diferentes epítopos de una proteína para contar todos los objetivos de proteínas simultáneamente usando un instrumento de Luminex. Para los ensayos multiplex ProcartaPlex se requieren tan solo 25 µl de plasma o suero, o 50 µl de sobrenadante del cultivo celular, y solo se necesitan cuatro horas para obtener los resultados analizados.

Las características incluyen:
• Resultados reproducibles y fiables: validados como panel según el estándar más alto del sector, incluidas las pruebas de combinación de proteínas diana y reactividad cruzada
• Más resultados por muestra: permite medir múltiples proteínas diana simultáneamente en una única muestra de 25–50 µL
• Tecnología Luminex consolidada: plataforma de multiplexing de referencia para detección y cuantificación de proteínas

Los ensayos ProcartaPlex utilizan la tecnología Luminex xMAP (método multianálito) para la detección y cuantificación simultáneas de hasta 65 proteínas diana en una única muestra de 25–50 µL de plasma, suero, sobrenadantes del cultivo celular y otros fluidos corporales.

Las microesferas de Luminex del ensayo de ProcartaPlex se tiñen internamente con proporciones precisas de fluoróforos rojos e infrarrojos para crear firmas específicas que pueden ser identificadas por los sistemas de detección Luminex xMAP (por ejemplo, Luminex 200, FLEXMAP 3D y MAGPIX). El ensayo ProcartaPlex, similar a un ELISA tipo sándwich, utiliza pares de anticuerpos emparejados para identificar la proteína de interés. En un ensayo multiplex, cada gránulo espectralmente único se etiqueta con anticuerpos específicos para una sola proteína diana, y las proteínas vinculadas se identifican con anticuerpos biotinilados y estreptavidina-R-ficoeritrina (RPE). La conjugación de anticuerpos específicos de proteínas en un gránulo distinto permite el análisis de varios elementos diana en un solo pocillo.

La diferencia más significativa entre un ensayo ProcartaPlex y uno ELISA es que el anticuerpo de captura del ensayo ProcartaPlex se conjuga en un gránulo y no se adsorbe en el pocillo de la microplaca, por lo que los reactivos del ensayo ProcartaPlex flotan en la solución. Para la detección, el instrumento Luminex 200, por ejemplo, contiene dos láseres, uno para distinguir la firma espectral de cada partícula y el segundo para cuantificar la cantidad de fluorescencia RPE, que es proporcional a la cantidad de proteína presente en la muestra. Los ensayos multiplex ProcartaPlex pueden determinar el perfil de más proteínas diana con mucha menos muestra en el mismo tiempo que se tarda en realizar un ELISA tipo sándwich tradicional.

Los paneles multiplex ProcartaPlex están disponibles en múltiples formatos en seis especies (humano, ratón, rata, primate no humano, porcino y canino). Visite thermofisher.com/procartaplex para obtener más información y consultar los productos disponibles.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Intervalo del ensayoVer certificado de análisis
Sensibilidad del ensayoMenos del 15 %
Para utilizar con (equipo)Instrumentos Luminex™
FormatoKit multiplex
Línea de productosProcartaPlex
Tipo de muestraSobrenadantes de cultivo celular, suero y plasma, Plasma, Cell Culture Supernatants
Volumen de muestraSuero, plasma: 25 μl; CCS: 50 μl
Condiciones de envíoHielo húmedo
CombinabilityCombinable
Tipo de productoPanel
Cantidad96 pruebas
Research AreaImmunology, Cytokines, Chemokines
EspecieRatón
Unit SizeEach
Contenido y almacenamiento
  • 2 viales de mezcla estándar de ratón A (liofilizada)
  • 2 viales de mezcla estándar de panel 1B de citocina de ratón (liofilizada)
  • 1 vial de mezcla de gránulos de captura B (1X)
  • 1 vial de mezcla de gránulos de captura C (1X)
  • 1 vial de mezcla de gránulos de captura D (1X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada B (50X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada C (50X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada D (50X)
  • 1 frasco de tampón de lectura (1X)
  • 1 frasco de tampón de lavado (10x)
  • 1 frasco de estreptavidina-PE (1X)
  • 1 frasco de tampón de ensayo universal (1 X)
  • 1 frasco de diluyente de anticuerpos de detección (1X)
  • Tira de 8 tubos
  • Película adhesiva
  • Placa de 96 pocillos de fondo plano, negra

Preguntas frecuentes

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Citations & References (21)

Citations & References
Abstract
Effector and Activated T Cells Induce Preterm Labor and Birth That Is Prevented by Treatment with Progesterone.
Authors:Arenas-Hernandez M, Romero R, Xu Y, Panaitescu B, Garcia-Flores V, Miller D, Ahn H, Done B, Hassan SS, Hsu CD, Tarca AL, Sanchez-Torres C, Gomez-Lopez N
Journal:J Immunol
PubMed ID:30918041
'Preterm labor commonly precedes preterm birth, the leading cause of perinatal morbidity and mortality worldwide. Most research has focused on establishing a causal link between innate immune activation and pathological inflammation leading to preterm labor and birth. However, the role of maternal effector/activated T cells in the pathogenesis of preterm ... More
Plasmodium co-infection protects against chikungunya virus-induced pathologies.
Authors:Teo TH, Lum FM, Ghaffar K, Chan YH, Amrun SN, Tan JJL, Lee CYP, Chua TK, Carissimo G, Lee WWL, Claser C, Rajarethinam R, Rénia L, Ng LFP
Journal:Nat Commun
PubMed ID:30254309
'Co-infection with Plasmodium and chikungunya virus (CHIKV) has been reported in humans, but the impact of co-infection on pathogenesis remains unclear. Here, we show that prior exposure to Plasmodium suppresses CHIKV-associated pathologies in mice. Mechanistically, Plasmodium infection induces IFN?, which reduces viraemia of a subsequent CHIKV infection and suppresses tissue viral ... More
Genetic Inactivation of ZCCHC6 Suppresses Interleukin-6 Expression and Reduces the Severity of Experimental Osteoarthritis in Mice.
Authors:Ansari MY, Khan NM, Ahmad N, Green J, Novak K, Haqqi TM
Journal:Arthritis Rheumatol
PubMed ID:30302948
'Cytokine expression is tightly regulated posttranscriptionally, but high levels of interleukin-6 (IL-6) in patients with osteoarthritis (OA) indicate that regulatory mechanisms are disrupted in this disorder. The enzyme ZCCHC6 (zinc-finger CCHC domain-containing protein 6; TUT-7) has been implicated in posttranscriptional regulation of inflammatory cytokine expression, but its role in OA ... More
MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Authors:Wu X, Nelson M, Basu M, Srinivasan P, Lazarski C, Zhang P, Zheng P, Sandler AD
Journal:J Immunother Cancer
PubMed ID:33757986
'MYC oncogene is deregulated in 70% of all human cancers and is associated with multiple oncogenic functions including immunosuppression in the tumor microenvironment. The role of MYC in the immune microenvironment of neuroblastoma and melanoma is investigated and the effect of targeting Myc on immunogenicity of cancer cells is evaluated.' ... More
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.
Authors:Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, Shaheen F, Collman RG, Karikó K, Danet-Desnoyers GA, Madden TD, Hope MJ, Weissman D
Journal:Nat Commun
PubMed ID:28251988
'Monoclonal antibodies are one of the fastest growing classes of pharmaceutical products, however, their potential is limited by the high cost of development and manufacturing. Here we present a safe and cost-effective platform for in vivo expression of therapeutic antibodies using nucleoside-modified mRNA. To demonstrate feasibility and protective efficacy, nucleoside-modified ... More